RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
  Emergency Medicine
  Internal Medicine
  Respiratory Medicine
   Asthma
   COPD
   Cystic Fibrosis
  Sexual Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Asthma Channel

subscribe to Asthma newsletter
Latest Research : Medicine : Respiratory Medicine : Asthma

   EMAIL   |   PRINT
Findings offer therapeutic potential for human asthma treatment

Jul 6, 2005 - 1:24:00 PM

The findings provide a better understanding of the human body’s defense mechanisms to stress, which may hold clues to better control the inflammation process and improve control over asthma and its symptoms.

 
[RxPG] Disruption of a single gene, Nrf2, plays a critical role in determining the susceptibility to asthma. A research team led by Shyam Biswal, PhD, at the Johns Hopkins Bloomberg School of Public Health found the absence of Nrf2 exacerbated allergen-mediated asthma in mice models. The study’s findings, published in the July 4, 2005, edition of the Journal of Experimental Medicine, may hold therapeutic potential for the treatment of human asthma.

Asthma is a complex inflammatory disease of the airway characterized by airway inflammation and hyperreactivity. The incidence of asthma has doubled in the past two decades in the United States, affecting 20 million Americans. Controlling inflammation is a focus of asthma therapy. Inflammation occurs when certain cells migrate into the airways. These “inflammatory” cells release reactive oxygen species (ROS), causing the airway lining to swell and restrict. ROS is thought to cause lung tissue damage as well. ROS levels are normally offset by antioxidants in non-asthmatics. Recently, researchers have been hunting for novel genes that regulate inflammation with the hope of developing them as targets for the next generation of asthma drugs.

Suspecting that a defect in antioxidant response exacerbates asthma severity, the team of researchers began looking into the genetic factors that might contribute to this deficiency. In 2002, Biswal’s lab discovered Nrf2 acts as a master regulator of the majority of antioxidant pathways and detoxifying enzymes for environmental pollutants. This led researchers to consider the role of Nrf2 in lung inflammatory diseases caused by exposure to allergens. They found that the absence of the Nrf2 gene increased migration of inflammatory cells into the airways and caused an enhanced asthmatic response in mice. “Nrf2 is critical for proper response to allergens in lungs and maintenance of a balance between ROS production. Antioxidant capability regulated by Nrf2 may be a major determinant of susceptibility to allergen-mediated asthma,” says Biswal. “Nrf2 regulated pathways seem to intervene inflammation at several points.”

The findings provide a better understanding of the human body’s defense mechanisms to stress, which may hold clues to better control the inflammation process and improve control over asthma and its symptoms. Study coauthor Tirumalai Rangasamy, PhD said that the next step for researchers will be to look for molecular mechanism of regulation of asthmatic inflammation by Nrf2 and determine if there are alterations in the response of Nrf2 gene in asthma-prone humans. Future studies will determine the therapeutic potential of targeting Nrf2 for treatment of asthma.



Publication: Journal of Experimental Medicine; “Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice” was written by Tirumalai Rangasamy, Jia Guo, Wayne A. Mitzner, Jessica Roman, Anju Singh, Allison D. Fryer, Masayuki Yamamoto, Thomas W. Kensler, Rubin M. Tuder, Steve N. Georas and Shyam Biswal.
On the web: http://www.jem.org/ 

Advertise in this space for $10 per month. Contact us today.


Related Asthma News
Breast-feeding babies staves off asthma risk
Mannose receptor plays a key role in allergic responses to cat dander
MEMS sensor for remote monitoring of asthmatic patients
Inhaled treatments work better for asthmatic kids
A dog in home may worsen asthma in children
PEAK Trial: Inhaled steroids do not prevent chronic asthma
Telithromycin antibiotic could help in asthma attack
Tomatoes, carrots can cut asthma risk
Inhaled steroid may work better for normal-weight people
Female foetus could increase expectant woman's asthma

Subscribe to Asthma Newsletter

Enter your email address:


 Additional information about the news article
The study was supported by grants from the National Institutes of Health, the National Institute of Environmental Health Sciences, the Maryland Cigarette Restitution Fund, the Flight Attendant Research Institute and the Thomas and Carol McCann Innovative Research Fund for Asthma and Respiratory Disease.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)